Navigation Links
Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
Date:8/24/2011

BELGRADE, Mont., Aug. 24, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Stifel Nicolaus 2011 Healthcare Conference. The conference will be held at the Four Seasons Hotel in Boston, Massachusetts on September 7-9, 2011.

Bacterin's chairman and CEO, Guy Cook, and CFO, John Gandolfo, are scheduled to present on Thursday, September 8, 2011 at 9:10 a.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company's business plan and objectives for the remainder of 2011.

The presentation will be available via webcast at www.veracast.com/webcasts/stifel/healthcare2011/61203587.cfm. A replay link will also be available for 90 days following the live presentation on the company's website at www.bacterin.com.

Bacterin recently reported record revenue for the second quarter 2011 of $7.5 million, up 25% sequentially and 135% year-over-year. The company also reported its first positive EBITDA quarter of $33,000.

For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Stifel representative.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications
'/>"/>

SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bacterin International Appoints Three New Members to Its Board of Directors
2. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
3. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
4. Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC
5. Bacterin International Updates Fourth Quarter and Full Year 2010 Financial Results
6. Bacterin International Secures $1.9 million in Private Placement
7. Bacterin International to Present at Noble Financial Capital Markets Seventh Annual Equity Conference on May 16, 2011
8. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
9. Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. Yongye Biotechnology International Retains CCG Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to ... hydrolyzed gluten in foods, has been accepted by AOAC International as Official First ... in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... and Industry Experience to ... ... ), a,leading, global full-service clinical research organization, today,announced the reappointment of ... was Executive Vice President and,Chief Financial Officer for Kendle from 1996 ...
... To Discuss the Data and Ongoing ... Clinical Development Programs, RICHMOND, Calif., Nov. ... data from its,SB-509-601 clinical trial, one of Sangamo,s three Phase 2 ... (DN). The data demonstrate that repeat administration of the,drug is well ...
... generation and improved HDL functionality are distinguishing ... NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ ... announce today key scientific data,was presented in ... of,RVX-208 at the American Heart Association Scientific ...
Cached Biology Technology:Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors 2Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6RVX-208 Data Demonstrates Increase in Functional HDL Particles 2RVX-208 Data Demonstrates Increase in Functional HDL Particles 3RVX-208 Data Demonstrates Increase in Functional HDL Particles 4
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... G&D, Dr. Guillermo Oliver (St. Jude Childrens ... resolve a century-old debate over the origin of ... the lymphatic vasculature is integral to understanding its ... tissue fluid levels) and disease (lymphedema and spreading ...
... of the scientific journal Science presents research on the ... that ultimately may lead to better diagnosis and treatment ... people every year. It may also bring an ... Giardia lamblia is an intestinal parasite that exists all ...
... Standards and Technology (NIST) today announced 56 ... development projects under the agencys Advanced Technology ... a broad range of technologies, including medical ... electronics, transportation, nanotechnology, energy conservation and automated ...
Cached Biology News:New Swedish research hope for millions of sufferers 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: